Compare Stitch Fix Inc (SFIX) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stitch Fix Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? Stitch Fix Inc trades at $2.38 (market cap $326.66M), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 22.5× Stitch Fix Inc's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Stitch Fix Inc for 31 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SFIX | SYRE | |
|---|---|---|
Market Cap | $326.66M | $7.35B |
Volume | 3,004,657 | 1,624,631 |
Sector | Consumer Cyclical | Health |
52-Week High | $5.64 | $108.92 |
52-Week Low | $2.16 | $22.18 |
Typical Hold Time | 31 Days | 0 Days |
Enterprise Value | $222.46M | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stitch Fix (SFIX) trades at $2.45, down 9.26% in the last session, reflecting negative sentiment following its Q4 2026 results and weak fiscal 2027 guidance. The stock exhibits a bearish technical trend, with key support at $2. Fundamentally, while revenue stabilized near $1.3B and net losses narrowed significantly to -$29M in FY2025, the company remains unprofitable with a negative net margin. Recent news highlights multiple law firm investigations and a post-earnings stock plunge due to cautious outlook.
The outlook is cautious. A low P/S ratio of 0.24 may attract value seekers, but persistent losses, negative cash flow, and declining active client projections pose substantial risks. Analyst consensus is mixed with a $3.40 price target, but the high proportion of Hold ratings (69.7%) signals skepticism about near-term recovery, emphasizing execution and demand challenges.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
